 Positive airway pressure ( PAP) therapy has been the standard treatment of choice for sleep disordered breathing , with 29-83 % of patients being noncompliant. With the advent of newly Food and Drug Adminisatration ( FDA)- approved implantable stimulators for treating sleep disordered breathing in a fraction of noncompliant PAP therapy patients , the landscape of sleep medicine and sleep technology is changing to narrow the gap between compliant and non-compliant patients. The remedē ® System for treating central sleep apnea and the Inspire ® upper airway stimulation ( UAS) therapy for treating obstructive sleep apnea are providing new tools for sleep physicians , elevating sleep technologists ' expertise , and paving the way for personalized medicine.